Suppr超能文献

随着体重增加,对雷加曲班的反应降低:一项基于人工智能的定量心肌灌注研究。

Reduced response to regadenoson with increased weight: An artificial intelligence-based quantitative myocardial perfusion study.

作者信息

Androulakis Emmanouil, Georgiopoulos Georgios, Azzu Alessia, Surkova Elena, Bakula Adam, Papagkikas Panagiotis, Briasoulis Alexandros, De Silva Ranil, Kellman Peter, Pennell Dudley, Alpendurada Francisco

机构信息

Royal Brompton and Harefield Hospitals, Guy's & St Thomas' NHS Foundation Trust, London, UK.

School of Biomedical Engineering and Imaging Sciences, Kings College London, London, UK.

出版信息

J Cardiovasc Magn Reson. 2024;26(2):101066. doi: 10.1016/j.jocmr.2024.101066. Epub 2024 Jul 25.

Abstract

BACKGROUND

There is conflicting evidence regarding the response to a fixed dose of regadenoson in patients with high body weight. The aim of this study was to evaluate the effectiveness of regadenoson in patients with varying body weights using novel quantitative cardiovascular magnetic resonance (CMR) perfusion parameters in addition to standard clinical markers.

METHODS

Consecutive patients with typical angina and/or risk factors for coronary artery disease (N = 217) underwent regadenoson stress CMR perfusion imaging using a dual-sequence quantitative protocol with perfusion parameters generated from an artificial intelligence (AI)-based algorithm. CMR was performed on 1.5T scanners using a standard 0.4 mg injection of regadenoson. A cohort of consecutive patients undergoing adenosine stress perfusion (N = 218) was used as a control group.

RESULTS

An inverse association of myocardial perfusion reserve and weight (mean decrease -0.05 per 10 kg increase, 95% confidence interval [CI] -0.009/-0.0001, P = 0.045) was noted in the regadenoson group but not in patients stressed with adenosine (P = 0.77). Adjusted logistic regression analysis revealed a 10 kg increase resulted in 36% increased odds for inadequate stress response (odds ratio [OR] = 1.36, 95% CI 1.10-1.69, P = 0.005). Moreover, a significant interaction (OR = 1.09, 95% CI 1.02-1.16, P = 0.012) between stressor type (regadenoson vs adenosine) and weight was noted. This was also confirmed in the propensity-matched subgroup (P = 0.024) and was not attenuated after adjustment (P = 0.041). Body surface area (BSA) (P = 0.006) but not body mass index (P = 0.055) was differentially associated with inadequate response conditional to the stressor used, and this association remained significant after adjustment for confounders (P = 0.025). Patients in the highest quartile of weight (>93 kg) or BSA (>2.06 m) had substantially increased odds for inadequate response with regadenoson (OR = 8.19, 95% CI 2.04-32.97, P = 0.003 for increased weight and OR = 7.75, 95% CI 1.93-31.13, P = 0.004 for increased BSA). Both weight and BSA had excellent discriminative ability for inadequate regadenoson response (receiver operating characteristic area under curves 0.84 and 0.83, respectively).

CONCLUSION

Using quantitative perfusion CMR in patients undergoing pharmacological stress with regadenoson, we found an inverse relationship between patient weight and both clinical response and myocardial perfusion parameters. A fixed-dose bolus approach may not be adequate to induce maximal hyperemia in patients with increased weight. Weight-adjusted stressors, such as adenosine, may be considered instead in patients with body weight >93 kg and BSA >2.06 m.

摘要

背景

关于高体重患者对固定剂量的瑞加诺生的反应,证据存在冲突。本研究的目的是除了使用标准临床指标外,还使用新型定量心血管磁共振(CMR)灌注参数来评估瑞加诺生在不同体重患者中的有效性。

方法

连续入选的典型心绞痛和/或有冠状动脉疾病危险因素的患者(N = 217)接受了瑞加诺生负荷CMR灌注成像,采用双序列定量方案,灌注参数由基于人工智能(AI)的算法生成。使用标准的0.4mg瑞加诺生注射剂在1.5T扫描仪上进行CMR检查。一组连续接受腺苷负荷灌注的患者(N = 218)作为对照组。

结果

在瑞加诺生组中观察到心肌灌注储备与体重呈负相关(每增加10kg平均下降-0.05,95%置信区间[CI]-0.009/-0.0001,P = 0.045),而在接受腺苷负荷的患者中未观察到这种相关性(P = 0.77)。校正后的逻辑回归分析显示,体重增加10kg导致负荷反应不足的几率增加36%(优势比[OR]=1.36,95%CI 1.10-1.69,P = 0.005)。此外,观察到负荷剂类型(瑞加诺生与腺苷)和体重之间存在显著的交互作用(OR = 1.09,95%CI 1.02-1.16,P = 0.012)。这在倾向匹配亚组中也得到了证实(P = 0.024),并且在调整后未减弱(P = 0.041)。根据所使用的负荷剂,体表面积(BSA)(P = 0.006)与反应不足存在差异相关,而体重指数(P = 0.055)则不然,并且在调整混杂因素后这种相关性仍然显著(P = 0.025)。体重或BSA处于最高四分位数(>93kg或>2.06m²)的患者使用瑞加诺生时反应不足的几率大幅增加(体重增加时OR = 8.19,95%CI 2.04-32.97,P = 0.003;BSA增加时OR = 7.75,95%CI 1.93-31.13,P = 0.004)。体重和BSA对瑞加诺生反应不足均具有出色的鉴别能力(受试者操作特征曲线下面积分别为0.84和0.83)。

结论

在接受瑞加诺生药物负荷的患者中使用定量灌注CMR,我们发现患者体重与临床反应及心肌灌注参数之间存在负相关。固定剂量推注方法可能不足以在体重增加的患者中诱导最大充血。对于体重>93kg且BSA>2.06m²的患者,可考虑使用如腺苷等根据体重调整的负荷剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/326e/11490868/d40bd847d4c8/ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验